Through CRISPR-Cas9 gene editing and preclinical CRC models, we demonstrated that CEP55 knockout leads to slower tumor growth, diminished immune suppressive markers, and a potential enhancement in responsiveness to anti-PD1 treatment. Here, CEP55 is linked to neoplasm.